Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's ...

Jim Cramer, the host of Mad Money, recently revisited one of his core investment principles: "Nobody ever made a dime ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

2-Year U.S. Treasury Note Continuous Contract $102.824-0.070-0.07% 5-Year U.S. Treasury Note Continuous Contract $106.383-0.234-0.22% 10-Year U.S. Treasury Note Continuous Contract $108.813-0.422 ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Invest in the best tech stocks today with Webull or Robinhood. The technology sector is made up of companies that operate in the semiconductor, artificial intelligence (AI), software, computer ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Nasdaq Data Link is a marketplace for financial, economic and alternative data delivered in modern formats for today's analysts, including Python, Excel.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...